Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Repligen Co. (NASDAQ:RGEN) has been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $189.57.

A number of equities analysts recently weighed in on RGEN shares. Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and reduced their price target for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Royal Bank of Canada reiterated an “outperform” rating and set a $190.00 target price on shares of Repligen in a research report on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Guggenheim initiated coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating for the company. Finally, Stephens reiterated an “overweight” rating and issued a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $153.82 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The stock has a market capitalization of $8.59 billion, a price-to-earnings ratio of 615.28, a PEG ratio of 5.72 and a beta of 0.95. The firm’s 50 day simple moving average is $137.40 and its 200-day simple moving average is $164.00. Repligen has a 12 month low of $110.45 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm’s revenue was down 3.2% on a year-over-year basis. During the same quarter last year, the business earned $0.53 earnings per share. Analysts expect that Repligen will post 1.45 EPS for the current year.

Insider Activity

In other Repligen news, Director Martin D. Madaus purchased 1,615 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were purchased at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the transaction, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Repligen news, Director Martin D. Madaus bought 1,615 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were acquired at an average cost of $124.94 per share, with a total value of $201,778.10. Following the purchase, the director now directly owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Repligen by 0.4% in the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after purchasing an additional 21,719 shares in the last quarter. Brown Capital Management LLC grew its stake in shares of Repligen by 5.8% in the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock worth $274,207,000 after acquiring an additional 83,416 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in shares of Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after acquiring an additional 199,322 shares during the period. Finally, Thrivent Financial for Lutherans raised its stake in shares of Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after acquiring an additional 425,061 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.